Jeffrey S. Hatfield - Net Worth and Insider Trading

Jeffrey S. Hatfield Net Worth

The estimated net worth of Jeffrey S. Hatfield is at least $5 Million dollars as of 2024-11-13. Jeffrey S. Hatfield is the CEO of Vitae Pharmaceuticals Inc and owns about 244,996 shares of Vitae Pharmaceuticals Inc (VTAE) stock worth over $5 Million. Details can be seen in Jeffrey S. Hatfield's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jeffrey S. Hatfield has not made any transactions after 2016-09-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jeffrey S. Hatfield

Jeffrey S. Hatfield Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jeffrey S. Hatfield owns 6 companies in total, including Viridian Therapeutics Inc (VRDN) , aTyr Pharma Inc (ATYR) , and Larimar Therapeutics Inc (LRMR) among others .

Click here to see the complete history of Jeffrey S. Hatfield’s form 4 insider trades.

Insider Ownership Summary of Jeffrey S. Hatfield

Ticker	Comapny	Transaction Date	Type of Owner
VRDN	Viridian Therapeutics Inc	2021-02-04	director
ATYR	aTyr Pharma Inc	2017-04-03	director
LRMR	Larimar Therapeutics Inc	2017-10-09	director & Chief Executive Officer
		2016-11-01	director
		2016-10-24	director & Chief Executive Officer
		2020-12-09	director

Jeffrey S. Hatfield Latest Holdings Summary

Jeffrey S. Hatfield currently owns a total of 1 stock. Jeffrey S. Hatfield owns 244,996 shares of Vitae Pharmaceuticals Inc (VTAE) as of September 14, 2016, with a value of $5 Million.

Latest Holdings of Jeffrey S. Hatfield

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
VTAE	Vitae Pharmaceuticals Inc	2016-09-14	244,996	21.00	5,144,916

Holding Weightings of Jeffrey S. Hatfield

Jeffrey S. Hatfield Form 4 Trading Tracker

According to the SEC Form 4 filings, Jeffrey S. Hatfield has made a total of 0 transactions in Vitae Pharmaceuticals Inc (VTAE) over the past 5 years. The most-recent trade in Vitae Pharmaceuticals Inc is the sale of 50,000 shares on September 14, 2016, which brought Jeffrey S. Hatfield around $1 Million.

Insider Trading History of Jeffrey S. Hatfield

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jeffrey S. Hatfield Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jeffrey S. Hatfield Ownership Network

Ownership Network List of Jeffrey S. Hatfield

No Data

Ownership Network Relation of Jeffrey S. Hatfield

Jeffrey S. Hatfield Owned Company Details

What does Viridian Therapeutics Inc do?

Who are the key executives at Viridian Therapeutics Inc?

Jeffrey S. Hatfield is the director of Viridian Therapeutics Inc. Other key executives at Viridian Therapeutics Inc include director & President and CEO Stephen F. Mahoney , Chief Operating Officer Thomas W. Beetham , and director & other: See Remarks Fairmount Healthcare Fund Ii Gp Llc .

Viridian Therapeutics Inc (VRDN) Insider Trades Summary

Over the past 18 months, Jeffrey S. Hatfield made no insider transaction in Viridian Therapeutics Inc (VRDN). Other recent insider transactions involving Viridian Therapeutics Inc (VRDN) include a net sale of 9,796 shares made by Lara Meisner , a net purchase of 1,600,000 shares made by Fairmount Healthcare Fund Ii Gp Llc , and a net purchase of 476,190 shares made by Fairmount Healthcare Fund Gp Llc .

In summary, during the past 3 months, insiders sold 0 shares of Viridian Therapeutics Inc (VRDN) in total and bought 1,626,400 shares, with a net purchase of 1,626,400 shares. During the past 18 months, 9,796 shares of Viridian Therapeutics Inc (VRDN) were sold and 2,102,590 shares were bought by its insiders, resulting in a net purchase of 2,092,794 shares.

Viridian Therapeutics Inc (VRDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viridian Therapeutics Inc Insider Transactions

No Available Data

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Jeffrey S. Hatfield is the director of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .

aTyr Pharma Inc (ATYR) Insider Trades Summary

Over the past 18 months, Jeffrey S. Hatfield made no insider transaction in aTyr Pharma Inc (ATYR). Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 65,000 shares made by Sanjay Shukla , a net purchase of 3,410 shares made by Jill Marie Broadfoot , and a net purchase of 100,000 shares made by Paul Schimmel .

In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,590 shares of aTyr Pharma Inc (ATYR) were sold and 225,000 shares were bought by its insiders, resulting in a net purchase of 223,410 shares.

aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.

aTyr Pharma Inc Insider Transactions

No Available Data

What does Larimar Therapeutics Inc do?

Who are the key executives at Larimar Therapeutics Inc?

Jeffrey S. Hatfield is the director & Chief Executive Officer of Larimar Therapeutics Inc. Other key executives at Larimar Therapeutics Inc include 10 percent owner & other: Possible Member of 10% Group James E Flynn , Chief Development Officer Gopi Shankar , and Chief Medical Officer Russell Clayton .

Larimar Therapeutics Inc (LRMR) Insider Trades Summary

Over the past 18 months, Jeffrey S. Hatfield made no insider transaction in Larimar Therapeutics Inc (LRMR). Other recent insider transactions involving Larimar Therapeutics Inc (LRMR) include a net purchase of 4,290,617 shares made by James E Flynn , a net purchase of 57,208 shares made by Thomas Edward Hamilton , and a net purchase of 5,000 shares made by Carole Ben-maimon .

In summary, during the past 3 months, insiders sold 0 shares of Larimar Therapeutics Inc (LRMR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Larimar Therapeutics Inc (LRMR) were sold and 4,367,575 shares were bought by its insiders, resulting in a net purchase of 4,367,575 shares.

Larimar Therapeutics Inc (LRMR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Larimar Therapeutics Inc Insider Transactions

No Available Data

What does InVivo Therapeutics Holdings Corp do?

Who are the key executives at InVivo Therapeutics Holdings Corp?

Jeffrey S. Hatfield is the director of InVivo Therapeutics Holdings Corp. Other key executives at InVivo Therapeutics Holdings Corp include 10 percent owner Brice Foose , Chief Financial Officer Richard Christopher , and director & CEO and CMO Richard M. Toselli .

InVivo Therapeutics Holdings Corp (NVIVQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of InVivo Therapeutics Holdings Corp (NVIVQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of InVivo Therapeutics Holdings Corp (NVIVQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

InVivo Therapeutics Holdings Corp (NVIVQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

InVivo Therapeutics Holdings Corp Insider Transactions

No Available Data

What does Vitae Pharmaceuticals Inc do?

Who are the key executives at Vitae Pharmaceuticals Inc?

Jeffrey S. Hatfield is the director & Chief Executive Officer of Vitae Pharmaceuticals Inc. Other key executives at Vitae Pharmaceuticals Inc include Chief Financial Officer Richard Steven Morris , General Counsel Scott Applebaum , and Chief Medical Officer Carole Sable .

Vitae Pharmaceuticals Inc (VTAE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Vitae Pharmaceuticals Inc (VTAE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vitae Pharmaceuticals Inc (VTAE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Vitae Pharmaceuticals Inc (VTAE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vitae Pharmaceuticals Inc Insider Transactions

No Available Data

What does Vir Biotechnology Inc do?

Who are the key executives at Vir Biotechnology Inc?

Jeffrey S. Hatfield is the director of Vir Biotechnology Inc. Other key executives at Vir Biotechnology Inc include Chief Executive Officer Backer Marianne De , Chief Technology Officer Ann M. Hanly , and Chief Financial Officer Sung Lee .

Vir Biotechnology Inc (VIR) Insider Trades Summary

Over the past 18 months, Jeffrey S. Hatfield made no insider transaction in Vir Biotechnology Inc (VIR). Other recent insider transactions involving Vir Biotechnology Inc (VIR) include a net sale of 952,542 shares made by Svf Endurance (cayman) Ltd , a net sale of 22,889 shares made by Phillip Pang , and a net sale of 55,500 shares made by George A Scangos .

In summary, during the past 3 months, insiders sold 20,337 shares of Vir Biotechnology Inc (VIR) in total and bought 0 shares, with a net sale of 20,337 shares. During the past 18 months, 1,173,278 shares of Vir Biotechnology Inc (VIR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,173,278 shares.

Vir Biotechnology Inc (VIR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vir Biotechnology Inc Insider Transactions

No Available Data

Jeffrey S. Hatfield Mailing Address

Above is the net worth, insider trading, and ownership report for Jeffrey S. Hatfield. You might contact Jeffrey S. Hatfield via mailing address: 11080 Roselle Street, San Diego Ca 92121.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.